Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Staying updated with the latest advancements in cancer care has never been easier. We published three new titles last year: Breast Cancer, Gynaecological Tumours and Lymphomas - all written with young oncologists in mind.
Be the force driving innovation in cancer drug development and make the latest advances in early clinical trials accessible to everyone in Asia.
Times are changing in hepatocellular carcinoma: new treatment strategies in early- and intermediate-stage disease and evolving options for systemic therapy. It is indicated for the treatment of patients with previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer. It is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.
Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology. The Molecular Analysis for Precision Oncology Congress MAP is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics.
The ESMO Congress taking place September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand. According to two international studies presented at the ESMO Congress , women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer , do not face an increased risk of recurrence or developing new breast cancers.
